p53 gene therapy for esophageal cancer

Journal of Gastroenterology

Volumn 37, Issue SUPPL. 14, 2002, Pages 87-91

  Shimada, Hideaki ^a   Matsubara, Hisahiro ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical study; Esophagel cancer; Gene therapy; p53

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; PROTEIN P53; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

EID: 0036854765     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03326422     Document Type: Article

References (41)

1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
2. Sugimachi K, Ohno S, Matsuda H, Mori M, Matsuoka H, Kuwano H. Clinicopathologic study of early stage esophageal carcinoma. Surgery (St. Louis) 1989;105:706-10.
3. Kato H. Diagnosis and treatment of esophageal neoplasms. Jpn J Cancer Res 1995;86:993-1009.
4. Isono K, Sato H, Nkaayma K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991;48:411-20.
5. Ancona E, Ruol A, Castoro C, Chiarion-Sileni V, Merigliano S, Santi S, et al. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. Ann Surg 1997;226: 714-24.
6. Ide H, Nakamura T, Hayashi K, Eguchi R, Tanigawa K, Ota M. Neoadjuvant chemotherapy with cisplatinum/5-fluorouracil/low-dose leucovorin for advanced squamous cell carcinoma of the esophagus. Semin Surg Oncol 1997;13:263-9.
7. Poplin EA, Jacobson J, Herskovic A, Panella TJ, Valdivieso M, Hutchins LF, Macdonald JS. Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer (Phila) 1996;78:1851-6.
8. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000;6:4663-73.
9. Okawa T, Dokiya T, Nishio M, Hishikawa Y, Morita K. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Int J Radiat Oncol Biol Phys 1999;45: 623-8.
10. Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989;17:49-54.
11. Zenone T, Romestaing P, Lambert R, Gerard JP. Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus. Eur J Cancer 1992;28A(8-9):1380-6.
12. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
13. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A 1990;87:9958-61.
14. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, et al. p53 mutation and protein accumulation during multi-stage human esophageal carcinogenesis. Cancer Res 1992;52: 6092-7.
15. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993;53: 1889-94.
16. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer (Phila) 1994;74:2218-23.
17. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer (Phila) 1998;83:7-18.
18. Kobayashi S, Koide Y, Endo M, Isono K, Ochiai T. The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 1999;177:497-502.
19. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 2000;31:403-5 [review].
20. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
21. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer (Phila) 1997;79:206-13.
22. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8.
23. Takebayashi Y, Natsugoe S, Baba M, Akiba S, Fukumoto T, Miyadera K, et al. Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer (Phila) 1999;85:282-9.
24. Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assel O, Nagasue N. The prognostic significance of micro vessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer (Phila) 1998;82:1225-32.
25. Shimada H, Takeda A, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer (Phila) 2001;92:663-9.
26. Shimada H, Takeda A, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma. Cancer (Phila) 2002 (in press).
27. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-60.
28. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;58: 2288-92.
29. Oota M, Shimada H, Takeda A, Nabeya Y, Okazumi S, Matsubara H, et al. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 2002 (in press).
30. Matsubara H, Kimura M, Sugaya M, Asano T, Ochiai T, Sakiyama S, Tagawa M. Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells. Int J Oncol 1999;14:1081-5.
31. Shimada H, Shimizu T, Ochiai T, Liu T, Sashiyama H, Nakamura A, et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001;31:597-604.
32. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91: 763-71.
33. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2000;19:1750-8.
34. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
35. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996;112: 1372-6; discussion 6-7.
36. Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, et al. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Int J Cancer 1997;7:367-70.
37. Swisher SG, Roth JA, Komaki R, et al. A phase II trial of adenoviral mediated p53 gene transfer (RPR/ING/IN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:461a.
38. Shimizu T, Shimada H, Ochiai T, Hamada H. Adenovirus-mediated gene therapy for esophageal carcinoma cells with fusion gene (uracil phosphoribosyl-transferase and herpes simplex virus thymidine kinase). Cancer Gene Ther 2001;8:512-21.
39. Saegusa M, Machida BD, Okayasu I. Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer (Phila) 2001;92:1177-89.
40. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997;3:313-9.
41. Shimada H, Liu T, Ochiai T, Shimizu T, Haupt Y, Hiwasa T, et al. Stimulation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33ING1 in T.Tn human esophageal carcinoma cells. Oncogene 2002;21:552-7.